SUPN peer analysis
Supernus Pharmaceuticals (SUPN) against its competitors: price, today's move, 1-year return and market value side by side.
SUPN and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | $20.38 | -1.02% | -10.38% | $3.55B |
| AVXL Anavex Life Sciences | $1.19 | -8.46% | -85.18% | $110.31M |
| AXSM Axsome Therapeutics | $130.48 | -9.66% | -2.01% | $7.57B |
| DNLI Denali Therapeutics | $18.70 | -1.27% | 14.16% | $3.03B |
| IONS Ionis Pharmaceuticals | $41.91 | -3.70% | -43.49% | $7.23B |
| JAZZ Jazz Pharmaceuticals | $215.23 | -0.35% | 57.91% | $14.02B |
| NBIX Neurocrine Biosciences | $145.40 | -0.48% | 5.33% | $14.85B |
| PRAX Praxis Precision Medicines | $277.32 | -3.01% | 37.97% | – |
| VNDA Vanda Pharmaceuticals | $3.79 | -6.42% | -12.27% | $229.18M |
| XENE Xenon Pharmaceuticals | $37.97 | 1.50% | -11.01% | $3.62B |
| SUPN Supernus Pharmaceuticals | $41.92 | 0.19% | -25.81% | $2.44B |
- SUPN's peers: ACAD (Acadia Pharmaceuticals), AVXL (Anavex Life Sciences), AXSM (Axsome Therapeutics), DNLI (Denali Therapeutics), IONS (Ionis Pharmaceuticals), JAZZ (Jazz Pharmaceuticals), NBIX (Neurocrine Biosciences), PRAX (Praxis Precision Medicines).
Updated 2026-11-02 17:14 UTC